Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBIT (2021 - 2026)

InMed Pharmaceuticals has reported EBIT over the past 5 years, most recently at -$2.1 million for Q4 2025.

  • For Q4 2025, EBIT rose 6.72% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.9 million, changed 0.17%, while the annual FY2025 figure was -$7.9 million, 3.05% up from the prior year.
  • EBIT for Q4 2025 was -$2.1 million at InMed Pharmaceuticals, down from -$1.8 million in the prior quarter.
  • Over five years, EBIT peaked at -$485150.0 in Q2 2023 and troughed at -$6.5 million in Q2 2022.
  • A 5-year average of -$2.5 million and a median of -$2.1 million in 2023 define the central range for EBIT.
  • Biggest five-year swings in EBIT: soared 92.56% in 2023 and later tumbled 319.3% in 2024.
  • Year by year, EBIT stood at -$4.3 million in 2021, then surged by 48.66% to -$2.2 million in 2022, then increased by 25.7% to -$1.6 million in 2023, then crashed by 37.03% to -$2.3 million in 2024, then grew by 6.72% to -$2.1 million in 2025.
  • Business Quant data shows EBIT for INM at -$2.1 million in Q4 2025, -$1.8 million in Q3 2025, and -$1.8 million in Q2 2025.